The robust glycolytic metabolism of glioblastoma multiforme (GBM) has proven them susceptible to increases in oxidative metabolism induced by the pyruvate mimetic dichloroacetate (DCA). Recent reports demonstrate that the anti-diabetic drug metformin enhances the damaging oxidative stress associated with DCA treatment in cancer cells. We sought to elucidate the role of metformin’s reported activity as a mitochondrial complex I inhibitor in the enhancement of DCA cytotoxicity in the VM-M3 model of GBM. We demonstrated that metformin potentiated DCA-induced superoxide production and that this was required for enhanced cytotoxicity towards VM-M3 cells with the combination. Similarly, rotenone enhanced oxidative stress resultant from DCA treatment and this too was required for the noted augmentation of cytotoxicity. Adenosine monophosphate kinase (AMPK) activation was not observed with the concentration of metformin required to enhance DCA activity. Moreover, addition of an activator of AMPK did not enhance DCA cytotoxicity, whereas an inhibitor of AMPK heightened the cytotoxicity of the combination. We also show that DCA and metformin reduce tumor burden and prolong survival in VM-M3 tumor-burdened mice as individual therapies. In contrast to our in vitro work, we did not observe synergy between DCA and metformin in vivo. Our data indicate that metformin enhancement of DCA cytotoxicity is dependent on complex I inhibition. Particularly, that complex I inhibition cooperates with DCA-induction of glucose oxidation to enhance cytotoxic oxidative stress in VM-M3 GBM cells. This work supports further investigation and optimization of a DCA/metformin combination as a potential pro-oxidant combinatorial therapy for GBM.

<p>Transplanting pancreatic islets into the liver through the portal vein is currently the most common procedure in clinical islet transplantations for treating patients with brittle type 1 diabetes. However, most islet grafts fail within a 5-year period necessitating retransplantation. The vascular connections are disrupted at islet isolation and implanted islets depend on diffusion of oxygen and nutrients in the immediate posttransplantation period. Rapid and efficient revascularization is of utmost importance for the survival and long-term function of transplanted islets. </p><p>In this thesis, the influence of the implantation microenvironment for islet engraftment and function was studied. Islets were transplanted into the liver, the renal subcapsular site or the pancreas. Islets implanted into the liver contained fewer glucagon-positive cells than islets implanted to the kidney and endogenous islets. Intraportally transplanted islets responded with insulin and glucagon release to secretagogues, but only when stimulated through the hepatic artery. Thus, the intrahepatic grafts were selectively revascularized from the hepatic artery. The vascular density in human islets transplanted into the liver of athymic mice was markedly lower when compared to human islets grafted to the kidney. Islets implanted into their physiological environment, the pancreas, were markedly better revascularized. Insulin content, glucose-stimulated insulin release, (pro)insulin biosynthesis and glucose oxidation rate were markedly decreased in transplanted islets retrieved from the liver, both when compared to endogenous and transplanted islets retrieved from the pancreas. Only minor changes in metabolic functions were observed in islets implanted into the pancreas when compared to endogenous islets. </p><p>The present findings demonstrate that the microenvironment has a major impact on the engraftment of transplanted islets. Elucidating the beneficial factors that promote engraftment would improve the survival and long-term function of transplanted islets. Ultimately, islet transplantation may be provided to an increased number of patients with type 1 diabetes.</p>

Transplanting pancreatic islets into the liver through the portal vein is currently the most common procedure in clinical islet transplantations for treating patients with brittle type 1 diabetes. However, most islet grafts fail within a 5-year period necessitating retransplantation. The vascular connections are disrupted at islet isolation and implanted islets depend on diffusion of oxygen and nutrients in the immediate posttransplantation period. Rapid and efficient revascularization is of utmost importance for the survival and long-term function of transplanted islets. In this thesis, the influence of the implantation microenvironment for islet engraftment and function was studied. Islets were transplanted into the liver, the renal subcapsular site or the pancreas. Islets implanted into the liver contained fewer glucagon-positive cells than islets implanted to the kidney and endogenous islets. Intraportally transplanted islets responded with insulin and glucagon release to secretagogues, but only when stimulated through the hepatic artery. Thus, the intrahepatic grafts were selectively revascularized from the hepatic artery. The vascular density in human islets transplanted into the liver of athymic mice was markedly lower when compared to human islets grafted to the kidney. Islets implanted into their physiological environment, the pancreas, were markedly better revascularized. Insulin content, glucose-stimulated insulin release, (pro)insulin biosynthesis and glucose oxidation rate were markedly decreased in transplanted islets retrieved from the liver, both when compared to endogenous and transplanted islets retrieved from the pancreas. Only minor changes in metabolic functions were observed in islets implanted into the pancreas when compared to endogenous islets. The present findings demonstrate that the microenvironment has a major impact on the engraftment of transplanted islets. Elucidating the beneficial factors that promote engraftment would improve the survival and long-term function of transplanted islets. Ultimately, islet transplantation may be provided to an increased number of patients with type 1 diabetes.

Les travaux présentés dans cette thèse visent à étudier les interfaces "nanocatalyseur/glucose" et "enzyme/O2" d'une biopile hybride. Dans ce cadre, une nouvelle méthode de synthèse de nanoparticules à base d'or et de platine a été développée. Ces nanomatériaux ont été caractérisés par différentes méthodes physicochimiques pour connaître leur taille, leur morphologie et leur dispersion dans un substrat carboné (Vulcan XC72R). La surface active de chaque électrode a été déterminée par voltammétrie cyclique et par CO stripping. Il a été montré que dans les catalyseurs AuxPty, l'or a un effet promoteur sur le platine vis-à-vis de l'oxydation du glucose. Le catalyseur Au70Pt30 présente la meilleure activité catalytique. L'étude par spectroélectrochimie a permis de déterminer que la B–gluconolactone est le produit primaire de l'oxydation du glucose qui procède à bas potentiel par la déshydrogénation du carbone anomérique sur le platine. La réaction de réduction de O2 a été catalysée par une enzyme, la bilirubine oxydase (BOD). Pour faciliter le transfert électronique, deux médiateurs : ABTS et un complexe d'osmium ont été encapsulés avec l'enzyme dans une matrice de Nafion® pour créer les interfaces : BOD/ABTS/O2 et BOD/Os/O2. L'étude voltammétrique des deux médiateurs en milieu tampon phosphate a révélé deux systèmes quasi-réversibles avec des potentiels apparents proches du potentiel redox du site T1 de la BOD. Bien que difficilement comparables en termes de densité de courant au catalyseur constitué de nanoparticules de platine, les cathodes enzymatiques permettent de catalyser à quatre électrons la réduction de O2 à des potentiels très proches du potentiel de Nernst. / The work developed in this thesis concerns the study of the behavior of redox reactions at the interfaces "nanocatalyst/glucose" and "enzyme/O2" for a hybrid Biofuel Cell. In this framework, a novel synthesis method of based gold and platinum nanoparticles has been achieved. These synthesized nanomaterials were characterized by different physicochemical techniques to determine their size, morphology and their dispersion in Vulcan XC72R used as substrate. The active surface area of each electrode material was determined by cyclic voltammetry and CO stripping. It has been shown that in the bimetallic catalyst gold promotes platinum activity towards the glucose oxidation. The bimetallic composition Au70Pt30 exhibits the better efficiency. The study by spectroelectrochemistry determined that the B-gluconolactone is the primary product of the glucose oxidation which proceeds at low potential by the dehydrogenation of anomeric carbon on platinum. The reduction reaction of O2 was catalyzed by an enzyme, bilirubin oxidase (BOD). Mediated electronic transfer was performed with two redox mediators, ABTS and an Osmium complex (Os). They have been encapsulated with the enzyme in a Nafion® matrix to construct the interfaces: BOD/ABTS/O2 and BOD/Os/O2. The voltammetric study of the mediators in phosphate buffer revealed two quasi-reversible systems with an apparent potential close to the theoretical potential of the T1 BOD center. Although hardly comparable in terms of current density with the Pt nanocatalyst the O2 reduction is a four electron reaction at the cathodes BOD/ABTS and BOD/Os which deliver an electrode potential close to the Nernst one.